Table 3.
Response to Pazopanib Based on Prior Therapy
| Prior treatment | Response to Study (Pazopanib) Therapy |
||||
|---|---|---|---|---|---|
| Partial Response by RECIST Criteria 1.0 | Stable Disease | Progressed Before/at Second Disease Evaluation | Discontinued for Reasons Other Than Due to Disease Progression Without Two Disease Evaluations | Response Rate (90% CI) | |
| None (n = 20) | 3 | 11 | 4 | 2 | 15% (4.2%–34.4%) |
| Non-TKI regimens (n = 5) | 1 | 3 | 1 | 0 | 20% (1.0%–65.7%) |
| TKI-containing regimen (n = 10) | 1 | 6 | 1 | 2 | 10% (0.5%–39.4%) |
Abbreviations: CI, confidence interval; TKI, tyrosine kinase inhibitor.